Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A9ZQ
|
||||
| Former ID |
DNC005642
|
||||
| Drug Name |
(3-Phenoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H16N2O2
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)C2=CN=C(O2)NC3=CC(=CC=C3)OC4=CC=CC=C4
|
||||
| InChI |
1S/C21H16N2O2/c1-3-8-16(9-4-1)20-15-22-21(25-20)23-17-10-7-13-19(14-17)24-18-11-5-2-6-12-18/h1-15H,(H,22,23)
|
||||
| InChIKey |
JTIZQZSOCSALNJ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancer | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY network | |||||
| Reactome | Neurophilin interactions with VEGF and VEGFR | ||||
| VEGF binds to VEGFR leading to receptor dimerization | |||||
| Integrin cell surface interactions | |||||
| EPHA-mediated growth cone collapse | |||||
| VEGFA-VEGFR2 Pathway | |||||
| VEGFR2 mediated cell proliferation | |||||
| WikiPathways | Focal Adhesion | ||||
| Nifedipine Activity | |||||
| Cardiac Progenitor Differentiation | |||||
| Signaling by VEGF | |||||
| Angiogenesis | |||||
| References | |||||
| REF 1 | J Med Chem. 2005 Mar 10;48(5):1610-9.Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.